FDA Approves Nelkarmi for ALK-Positive Lung Cancer
Accelerated approval covers adults with locally advanced or metastatic ALK-positive non-small cell lung cancer who have had prior ALK-targeted therapy.
Updated on Nov. 17, 2026 in Cancer

The FDA granted accelerated approval to neladalkib, marketed as Nelkarmi by Nuvalent, Inc., on November 17, 2026. The kinase inhibitor is indicated for adults with previously treated ALK-positive non-small cell lung cancer.
Why it matters
The approval gives patients whose disease has progressed on earlier ALK inhibitors a new oral treatment option. Accelerated approval is based on response rates, so continued confirmatory evidence will be needed to establish longer-term benefit.
Response rates came from a single-arm trial of 222 patients, with confirmed overall response rates of 49% after one prior alectinib-containing therapy and 32% after two or more prior ALK TKIs and chemotherapy. The trial had no control arm, and the duration of response beyond the reported 6- and 12-month thresholds remains unresolved.
The players
Nuvalent, Inc.
Nuvalent is a clinical-stage biopharmaceutical company developing targeted therapies for cancer, and it markets neladalkib as Nelkarmi.
U.S. Food and Drug Administration (FDA)
The FDA is the U.S. federal agency responsible for regulating drugs and granting approvals for therapies sold in the United States.
The details
Patients take 150 mg orally once daily with or without food until disease progression or unacceptable toxicity. The prescribing information carries warnings for hepatotoxicity, renal toxicity, ocular toxicity, creatine phosphokinase elevation and embryo-fetal toxicity, and the most common adverse reactions include hepatotoxicity, musculoskeletal pain, constipation and fatigue.
Timeline
November 17, 2026: FDA grants accelerated approval to neladalkib (Nelkarmi).
Treatment Sequencing
The approval adds another step to the sequence of ALK-targeted therapies that began with earlier inhibitors such as alectinib, giving clinicians a later-line option for patients whose disease has progressed. It follows the accelerated-approval pathway the FDA has used for targeted lung cancer drugs based on response rates from single-arm trials.
Patients with ALK-positive lung cancer who have progressed on prior ALK inhibitors may now have access to an oral, once-daily option. Treatment requires monitoring for liver, kidney, eye and muscle-enzyme effects, so patients should discuss these warnings with their oncology team.
The takeaway
Patients on ALK-targeted therapy should ask their oncologist how the warnings for liver, kidney and eye toxicity apply to their own treatment plan. Response rates from single-arm trials are an early signal, so follow-up data on how long responses last will matter.
Further reading
Explore more on Cancer treatments and drug approvals.






